The Chairman & CEO of TaiGen Biotechnology discusses the growth opportunities that the company holds in China, its main target market, and documents how her long-term strategic outlook made the company one of the most successful biotech companies in the region today, holding an unrivalled experience and unique positioning in the world’s second largest pharmaceutical market.
You created TaiGen Biotechnology 15 years ago, what is for you the most meaningful achievement so far?
"China is home to 25 percent of all hepatitis C patients worldwide, making the country a 40 million-patient market in this therapeutic area."
